ClinicalTrials.gg
CompletedNCT05417906Updated Oct 28, 2026

Using the Blood Eosinophil Count to Guide Systemic Corticosteroid Treatment in Asthma Exacerbations

A Phase 2 interventional study of Standard care and Eosinophil-directed care in Asthma Attack and Asthma, sponsored by Changi General Hospital. Completed at 2 sites in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Changi General Hospital · Phase 2, Interventional, and Treatment

How we know

Updated Oct 28, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Asthma with a site in Singapore — 3 open to participants now, 3 under way, 1 of them phase 3. Asthma · Singapore.

Enrollment
17th of 19
110 · median 253
Started
2022
the only one that year
Phase 2
7 of 25
none open now
Registered
21st of 25
by date
Lead sponsor
2 of 25
Changi General Hospital

Among the 25 studies in Asthma with a site in Singapore, this one is the 17th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 2, and was the 21st registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 25 studies in Asthma with a site in Singapore are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Asthma with a site in Singapore, or all of them as a file.
02

Study summary

Asthma attacks which are moderate-to-severe are typically treated with corticosteroids, but the optimal treatment duration is unknown and treatment responses can be variable. Inadequate treatment may compromise recovery, but increased exposure to corticosteroids is, in turn, associated with drug-related adverse effects.

There is a need for a biomarker to guide duration of corticosteroid treatment in asthma attacks. One such candidate biomarker is the blood eosinophil count, which may predict steroid-responsiveness. We hypothesize that the blood eosinophil count can potentially be used as a biomarker to guide the duration of corticosteroids in moderate-to-severe asthma attacks.

This study will recruit individuals hospitalized for asthma attack. Participants will be randomized to standard care or blood-eosinophil guided systemic corticosteroid therapy. Subjects in the standard arm will receive oral corticosteroids for a total of 5 days. Subjects in the blood-eosinophil guided arm will receive oral corticosteroids for a total of 5 days if admission eosinophil count is ≥ 0.300 x 10\^3/µL, and receive 3 days of oral corticosteroids if the admission blood eosinophil is \< 0.300 x 10\^3/µL. The rate of treatment failure will be compared between these two groups.

03

Conditions studied

  • Asthma Attack
  • Asthma

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 21 years old
  2. Admitted for acute exacerbation of asthma and have received ≤ 3 days of systemic
  3. Have a had a blood eosinophil count (as part of routine clinical care) drawn before administration of systemic corticosteroid
  4. Have not taken SCS within 7 days prior to presentation to hospital

Exclusion criteria

Exclusion Criteria:

  1. Concomitant pneumonia
  2. Admission to high-dependency/intensive care unit, or requirement for invasive/noninvasive mechanical ventilation
  3. Eosinophilia due to other known causes (eosinophilic granulomatosis and polyangiitis, parasitic infections, )
  4. Other concomitant respiratory conditions e.g. , bronchiectasis
  5. Those on anti-IL5 or anti-IL5R treatment
  6. Pregnant subjects
  7. Subjects who are already on an drug or has been participating in another clinical study with an investigational product within the last 6 months
  8. Subjects deemed by investigators to have a of \< 12 months (any cause)
  9. Prisoners
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (actual)

Study arms

  • Active comparator
    Standard care

    Other: Standard care

  • Experimental
    Eosinophil-directed care

    Other: Eosinophil-directed care

Interventions

  • OtherStandard care

    Oral prednisolone for 5 days

  • OtherEosinophil-directed care

    Oral prednisolone for 5 days if eosinophil count is ≥ 0.300 x 10\^3/µL, or 3 days if eosinophil is \< 0.300 x 10\^3/µL

06

What researchers measure

Primary outcomes

  1. Proportion of participants experiencing treatment failure

    Defined as death from any cause, or need for invasive/noninvasive mechanical ventilation, or need to restart/extend systemic steroid treatment

    Time frame: Through the duration of the index admission for asthma attack, typically 3-5 days

Secondary outcomes

  1. Length of hospital stay (number of days)

    Time frame: Through the duration of the index admission for asthma attack, typically 3-5 days

  2. Cumulative steroid dose at index admission (mg prednisolone-equivalent)

    Time frame: Through the duration of the index admission for asthma attack, typically 3-5 days

  3. Proportion of participants receiving additional systemic steroid course within 14 days

    Time frame: 14 days

  4. Asthma Control Questionnaire-5

    Time frame: At baseline, 7, 14, 30 and 90 days

  5. Proportion of participants experiencing all-cause death

    Time frame: 30 and 90 days

  6. Proportion of participants who develop pneumonia

    Time frame: 30 and 90 days

  7. Proportion of participants who develop venous thromboembolism

    Time frame: 30 and 90 days

  8. Proportion of participants who develop sepsis

    Time frame: 30 and 90 days

  9. Proportion of participants who develop fractures

    Time frame: 30 and 90 days

  10. Proportion of participants who develop upper gastrointestinal bleeds/peptic or gastric ulcers

    Time frame: 30 and 90 days

  11. Time to next emergency department visit or admission for asthma

    Time frame: 1 year

07

Study locations

2 sites
  • Singapore General Hospital
    Singapore, Singapore 168753, Singapore
  • Changi General Hospital
    Singapore, Singapore 529889, Singapore
08

References and documents

Publications

  • Yii A, Tay TR, Lee KCH, Chew SY, Sieow NY, Choo XN, Toh MR, Loh SCH, Tiew PY, Koh JMK, Tee AKH, Koh MS. Blood eosinophil-guided systemic corticosteroid duration in adults hospitalised for asthma exacerbation: a randomised, controlled, open-label, non-inferiority trial. Thorax. 2026 Feb 16;81(3):238-245. doi: 10.1136/thorax-2025-223961. PubMed 41339088 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in May 2024, 23 months.

Of 62 non-industry phase 2 interventional studies under Asthma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 62. This study's 23 months is below that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Sep 2025 → May 2024 and completion Sep 2026 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2022
First posted
Jun 14, 2022
StartActual
Jun 2, 2022
Primary completionActual
May 19, 2024was Sep 2025
CompletionActual
Apr 12, 2026was Sep 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 28, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 Singapore)
  • Singapore General Hospital · Singapore, Singapore
  • Changi General Hospital · Singapore, Singapore
Show 2 removed
  • Singapore General Hospital · Singapore, Singapore
  • Changi General Hospital · Singapore, Singapore
Oct 28, 2026
Primary completion
Sep 30, 2025→May 19, 2024 (actual)
Oct 28, 2026
Study completion
Sep 30, 2026→Apr 12, 2026 (actual)
Oct 28, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41339088 ↗
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Active, not recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41339088 ↗
    2 sites added, 2 sites removed
    Show 2 added (2 Singapore)
    • Singapore General Hospital · Singapore, Singapore
    • Changi General Hospital · Singapore, Singapore
    Show 2 removed
    • Singapore General Hospital · Singapore, Singapore
    • Changi General Hospital · Singapore, Singapore
    Primary completion Sep 30, 2025→May 19, 2024 (now actual)
    Study completion Sep 30, 2026→Apr 12, 2026 (now actual)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05417906
Responsible party
Sponsor
First posted
Jun 14, 2022
Start date
Jun 2, 2022
Primary completion
May 19, 2024
Completion
Apr 12, 2026
Last update
Oct 28, 2026

Study contacts

Anthony Yii, MB BChir
principal investigator · Changi General Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion